✦ LIBER ✦

484 Biological markers associated with sensitivity of tumour cells to the epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 and ionizing radiation

✍ Scribed by S. Burdak-Rothkamm; C.E. Ruebe; T.P. Nguyen; D. Ludwig; K. Feldmann; T. Wiegel; C. Ruebe

Book ID: 118620658
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 169 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90516-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of ZD1839 (IressaTM), an epid

The effect of ZD1839 (IressaTM), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells

✍ A. Al-Hazzaa; I. D. Bowen; P. Randerson; M. A. Birchall 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

Ocular findings in patients with solid t

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials

✍ Murray, P I; Bristow, E; Forsythe, B J; Faulkner, K; Tullo, A B; Esmaeli, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 187 KB

ZD1839, a selective epidermal growth fac

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer

✍ David Raben; Barbara A. Helfrich; Dan Chan; Gary Johnson; Paul A. Bunn Jr 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 107 KB

ZD1839 (Iressa), a novel epidermal growt

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro

880 Prostate cancer cell proliferation i

880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’)

✍ M. Bologna; A. Angelucci; C. Festuccia; G.L. Gravina; P. Muzi; C. Vicentini 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant